Perspectives and challenges in developing small molecules targeting purine nucleoside phosphorylase

Eur J Med Chem. 2024 Apr 20;271:116437. doi: 10.1016/j.ejmech.2024.116437. Online ahead of print.ABSTRACTAs a cytosolic enzyme involved in the purine salvage pathway metabolism, purine nucleoside phosphorylase (PNP) plays an important role in a variety of cellular functions but also in immune system, including cell growth, apoptosis and cancer development and progression. Based on its T-cell targeting profile, PNP is a potential target for the treatment of some malignant T-cell proliferative cancers including lymphoma and leukemia, and some specific immunological diseases. Numerous small-molecule PNP inhibitors have been developed so far. However, only Peldesine, Forodesine and Ulodesine have entered clinical trials and exhibited some potential for the treatment of T-cell leukemia and gout. The most recent direction in PNP inhibitor development has been focused on PNP small-molecule inhibitors with better potency, selectivity, and pharmacokinetic property. In this perspective, considering the structure, biological functions, and disease relevance of PNP, we highlight the recent research progress in PNP small-molecule inhibitor development and discuss prospective strategies for designing additional PNP therapeutic agents.PMID:38701712 | DOI:10.1016/j.ejmech.2024.116437
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Source Type: research